ARDS Shares Outstanding History
Below is a table of the ARDS shares outstanding history going back to 8/14/2018:

Date ARDS Shares Outstanding

Also see: ARDS Market Cap History
ARDS Historical Shares Outstanding:
+25.85% CAGR
ARDS Historical Shares Outstanding: +25.85% CAGR

Mouse over chart for data details
8/14/2018 ...10/31/2022
Aridis Pharmaceuticals is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using human monoclonal antibodies (mAbs) to treat infections. Co.'s product candidates include: AR-301, which is a human immunoglobulin 1 (IgG1) mAb targeting the gram-positive bacteria S. aureus alphatoxin; AR-320, which is a human, IgG1 monoclonal antibody targeting S. aureus alpha toxin; AR-501 (Panaecin), which is a spectrum small molecule anti-infective Co. is developing in addition to its targeted mAb product candidates; and AR-101, which is a human immunoglobulin M mAb targeting the gram-negative bacteria P. aeruginosa serotype O11. We show 17 historical shares outstanding datapoints in our coverage of ARDS's shares outstanding history.

Understanding the changing numbers of ARDS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ARDS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ARDS by allowing them to research ARDS shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree ARDS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aridis Pharmaceuticals (ARDS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ARDX Shares Outstanding History
ARMO Shares Outstanding History
ARNA Shares Outstanding History
ARPO Shares Outstanding History
ARQL Shares Outstanding History
ARQT Shares Outstanding History
ARTL Shares Outstanding History
ARVN Shares Outstanding History
ARWR Shares Outstanding History
ASMB Shares Outstanding History
More Healthcare companies »


ARDS Shares Outstanding History | | Copyright © 2017 - 2022, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.